Austria's Regulatory Chief Secures Top EMA Job
Dr. Christa Wirthumer-Hoche has been elected as the new chair of the Management Board of the European Medicines Agency (EMA).
Dr. Christa Wirthumer-Hoche has been elected as the new chair of the Management Board of the European Medicines Agency (EMA). The post is for a three-year period, and she succeeds Kent Woods, who stepped down as chair of the Board in December.
Wirthumer-Hoche has been head of the Austrian Medicines and Medical Devices Agency since October 2013, and has served as vice-chair of EMA’s Management Board since March 2015. She is also co-chair of the EU Network Training Center that was launched in January 2015 and has served as chair of EMA’s Active Substance Master File Working Group.
“As chair, my ambition is to ensure a strong partnership between EMA, the European Union national competent authorities and the European Commission to guarantee that EMA is able to fulfil its important role of safeguarding human and animal health in Europe,” said Wirthumer-Hoche, who holds a doctorate from the Technical University of Vienna and a diploma in chemistry and biochemistry.
The Management Board sets the EMA’s budget, approves the annual work program, and is responsible for ensuring that the agency works effectively and co-operates successfully with partner organizations across the EU and beyond.
In her statement dated October 19, 2015, Wirthumer-Hoche declared no conflicts of interest. Her replacement as the vice-chair has not been announced yet.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
